Previous studies have shown that PI3K-AKT activation of EGFR signaling upregulates survivin expression, and persistent survivin expression is associated with erlotinib-resistance in EGFR mutation-positive NSCLC cells [42]. The gene discussed is BIRC5; the disease is non-small cell lung carcinoma.